Savara Q1 FY26 net loss widens to $37.3 million; R&D expense rises 22.1% to $23.4 million

• Savara posted a first-quarter net loss of USD 37.3 million, or USD 0.15 per share, widening from a loss of USD 26.6 million, or USD 0.12 per share, a year earlier.
• Research and development expense rose 22.1% to USD 23.4 million, driven by MOLBREEVI program tasks including USD 2.5 million of chemistry, manufacturing and controls costs, partly offset by lower regulatory and clinical costs.
• General and administrative expense climbed 68.4% to USD 15.6 million on higher personnel costs tied to share-based compensation.
• Cash, cash equivalents and short-term investments totaled about USD 202.8 million at March 31, with debt of about USD 30.1 million.
• FDA filed MOLBREEVI biologics license application with a PDUFA target action date of Nov. 22, 2026; EMA and U.K. MHRA validated marketing applications with decisions expected in Q1 2027 and Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605121605BIZWIRE_USPR_____20260512_BW677993) on May 12, 2026, and is solely responsible for the information contained therein.